Dose–response modelling for bivariate covariates with and without a spike at zero: theory and application to binary outcomes. (16th March 2015)

• Record Type: Journal Article
• Authors: Lorenz, E.; Jenkner, C.; Sauerbrei, W.; Becher, H.
• Is Part Of: Statistica Neerlandica. Volume 69:Number 4(2015:Nov.)
• Page Start: 374
• Page End: 398
• Publication Date: 2015-03-16
• Subjects: Statistics -- Periodicals; 519.5; 314.92
• DOI: 10.1111/stan.12064
• Languages: English
• ISSNs: 0039-0402

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>In epidemiology and clinical research, there is often a proportion of unexposed individuals resulting in zero values of exposure, meaning that some individuals are not exposed and those exposed have some continuous distribution. Examples are smoking or alcohol consumption. We will call these variables with a spike at zero (SAZ). In this paper, we performed a systematic investigation on how to model covariates with a SAZ and derived theoretical odds ratio functions for selected bivariate distributions. We consider the bivariate normal and bivariate log normal distribution with a SAZ. Both confounding and effect modification can be elegantly described by formalizing the covariance matrix given the binary outcome variable <italic>Y</italic>. To model the effect of these variables, we use a procedure based on fractional polynomials first introduced by Royston and Altman (1994, <italic>Applied Statistics</italic> 43: 429–467) and modified for the SAZ situation (Royston and Sauerbrei, 2008, <italic>Multivariable model‐building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables</italic>, Wiley; Becher <italic>et al</italic>., 2012, <italic>Biometrical Journal</italic> 54: 686–700). We aim to contribute to theory, practical procedures and application in epidemiology and clinical research to derive multivariable models for variables with a SAZ. As an example, we use data from a case–control study on lung cancer.</p> </abstract>